Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets
Small-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, invariably relapses and acquires a multidrug chemoresistant phenotype that generally renders retreatment with first-line therapy both futile and counterproductive. This report presents the case of a 77-...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2016-05-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | http://www.karger.com/Article/FullText/446209 |
| id |
doaj-c53dfe35928f46b0a955e22b98939a7c |
|---|---|
| record_format |
Article |
| spelling |
doaj-c53dfe35928f46b0a955e22b98939a7c2020-11-24T21:27:17ZengKarger PublishersCase Reports in Oncology1662-65752016-05-019228528910.1159/000446209446209Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum DoubletsCorey A. CarterBryan OronskyScott CaroenJan ScicinskiAiste DegesysPedro CabralesTony R. ReidChristina BrzezniakSmall-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, invariably relapses and acquires a multidrug chemoresistant phenotype that generally renders retreatment with first-line therapy both futile and counterproductive. This report presents the case of a 77-year-old Caucasian male with extensive-stage refractory SCLC who was restarted on platinum doublets as part of a clinical trial called TRIPLE THREAT (NCT02489903) involving pretreatment with the epi-immunotherapeutic agent RRx-001, and who achieved a partial response after only 4 cycles. The patient had received a platinum drug twice before, in 2009 for a diagnosis of non-small-cell lung cancer (squamous cell carcinoma) and in 2015 for SCLC, suggesting that RRx-001 pretreatment may sensitize or resensitize refractory SCLC patients to first-line chemotherapy.http://www.karger.com/Article/FullText/446209Partial responseRRx-001Refractory small-cell lung cancerPlatinum doublets |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Corey A. Carter Bryan Oronsky Scott Caroen Jan Scicinski Aiste Degesys Pedro Cabrales Tony R. Reid Christina Brzezniak |
| spellingShingle |
Corey A. Carter Bryan Oronsky Scott Caroen Jan Scicinski Aiste Degesys Pedro Cabrales Tony R. Reid Christina Brzezniak Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets Case Reports in Oncology Partial response RRx-001 Refractory small-cell lung cancer Platinum doublets |
| author_facet |
Corey A. Carter Bryan Oronsky Scott Caroen Jan Scicinski Aiste Degesys Pedro Cabrales Tony R. Reid Christina Brzezniak |
| author_sort |
Corey A. Carter |
| title |
Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets |
| title_short |
Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets |
| title_full |
Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets |
| title_fullStr |
Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets |
| title_full_unstemmed |
Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets |
| title_sort |
partial response in an rrx-001-primed patient with refractory small-cell lung cancer after a third introduction of platinum doublets |
| publisher |
Karger Publishers |
| series |
Case Reports in Oncology |
| issn |
1662-6575 |
| publishDate |
2016-05-01 |
| description |
Small-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, invariably relapses and acquires a multidrug chemoresistant phenotype that generally renders retreatment with first-line therapy both futile and counterproductive. This report presents the case of a 77-year-old Caucasian male with extensive-stage refractory SCLC who was restarted on platinum doublets as part of a clinical trial called TRIPLE THREAT (NCT02489903) involving pretreatment with the epi-immunotherapeutic agent RRx-001, and who achieved a partial response after only 4 cycles. The patient had received a platinum drug twice before, in 2009 for a diagnosis of non-small-cell lung cancer (squamous cell carcinoma) and in 2015 for SCLC, suggesting that RRx-001 pretreatment may sensitize or resensitize refractory SCLC patients to first-line chemotherapy. |
| topic |
Partial response RRx-001 Refractory small-cell lung cancer Platinum doublets |
| url |
http://www.karger.com/Article/FullText/446209 |
| work_keys_str_mv |
AT coreyacarter partialresponseinanrrx001primedpatientwithrefractorysmallcelllungcancerafterathirdintroductionofplatinumdoublets AT bryanoronsky partialresponseinanrrx001primedpatientwithrefractorysmallcelllungcancerafterathirdintroductionofplatinumdoublets AT scottcaroen partialresponseinanrrx001primedpatientwithrefractorysmallcelllungcancerafterathirdintroductionofplatinumdoublets AT janscicinski partialresponseinanrrx001primedpatientwithrefractorysmallcelllungcancerafterathirdintroductionofplatinumdoublets AT aistedegesys partialresponseinanrrx001primedpatientwithrefractorysmallcelllungcancerafterathirdintroductionofplatinumdoublets AT pedrocabrales partialresponseinanrrx001primedpatientwithrefractorysmallcelllungcancerafterathirdintroductionofplatinumdoublets AT tonyrreid partialresponseinanrrx001primedpatientwithrefractorysmallcelllungcancerafterathirdintroductionofplatinumdoublets AT christinabrzezniak partialresponseinanrrx001primedpatientwithrefractorysmallcelllungcancerafterathirdintroductionofplatinumdoublets |
| _version_ |
1725975635480805376 |